Back to results
US 2020/0046811 A1Published application
Methods and compositions for modulating fgf23 levels
AssigneeNorthwestern University
InventorsDouglas E. Vaughan, Mesut Eren, Aaron T. Place, Toshio Miyata
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions, systems, and methods for treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) with a composition comprising: i) an agent that causes an increase in expression of urokinase plasminogen activator (uPA) and/or tissue plasminogen activator (tPA), ii) purified uPA, and/or purified tPA.
Claims20
A method of treating a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23) comprising:
- administering and/or prescribing at least one of the following to a subject with a condition characterized by elevated FGF23:
- i) a first composition comprising an agent that causes an increase in expression of a serine protease selected from urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA);
- and
- ii) a second composition comprising purified uPA, uPA derivative, tPA, and/or a tPA derivative.
1 more element
A system comprising:
- a) a first component selected from:
- i) a first composition comprising an agent that causes an increase in expression of a serine protease selected from urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA);
- and
- ii) a second composition comprising purified uPA, uPA derivative, tPA, and/or tPA derivative;
- and
- b) a second component comprising a report characterizing a subject as having elevated levels of FGF23 and/or having a condition characterized by elevated Fibroblast Growth Factor 23 (FGF23).
3 more elements
A system comprising:
- a) a first component selected from:
- i) a first composition comprising an agent that causes an increase in expression of a serine protease selected from urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA);
- and
- ii) a second composition comprising purified uPA, uPA derivative, tPA, and/or tPA derivative;
- and
- b) a second component comprising components for testing a sample from a subject to detect FGF23 levels.
3 more elements
Dependencies are inferred from the claim text.